Hepatitis C virus and vaccine development.

PubWeight™: 0.80‹?›

🔗 View Article (PMC 4293608)

Published in Int J Mol Cell Med on January 01, 2014

Authors

Malihe Naderi1, Naghmeh Gholipour2, Mohammad Reza Zolfaghari1, Maryam Moradi Binabaj3, Ahmad Yegane Moghadam4, Gholamreza Motalleb5

Author Affiliations

1: Department of Microbiology, Qom branch, Islamic Azad University, Qom 37185-364, Iran .
2: National Institute of Genetic Engineering and Biotechnology, Department of Molecular Genetics, Tehran, Iran .
3: Department of Clinical Biochemistry, Faculty of Medicine, Golestan University of Medical Sciences, Golestan, Iran.
4: Department of Otolaryngology, Kashan University of Medical Sciences, Kashan, Iran.
5: Department of Biology, Faculty of Science, University of Zabol, Zabol, Iran.

Articles citing this

Tackling the Hepatitis C Disease Burden in Punjab, India. J Clin Exp Hepatol (2016) 0.75

Viral hepatitis: Indian scenario. Med J Armed Forces India (2016) 0.75

Combating the wrath of viral hepatitis in India. Indian J Med Res (2016) 0.75

Status of hepatitis C virus vaccination: Recent update. World J Gastroenterol (2016) 0.75

Articles cited by this

Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A (1991) 14.05

Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci U S A (1990) 9.98

Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups. Proc Natl Acad Sci U S A (1990) 8.92

Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci U S A (1991) 7.15

Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J Virol (1993) 6.36

HCV persistence and immune evasion in the absence of memory T cell help. Science (2003) 5.23

Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A (1996) 4.82

Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol (1993) 4.57

Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med (2003) 4.20

Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A (1994) 3.76

Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A (1994) 3.56

Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA (2003) 3.25

Biosynthesis and biochemical properties of the hepatitis C virus core protein. J Virol (1994) 3.19

Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A (2007) 3.13

Formation of native hepatitis C virus glycoprotein complexes. J Virol (1997) 2.87

Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci U S A (1994) 2.83

Processing of the envelope glycoproteins of pestiviruses. J Virol (1993) 2.79

The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor. Biochem Biophys Res Commun (1993) 2.67

On the role of antigen in maintaining cytotoxic T-cell memory. Proc Natl Acad Sci U S A (1996) 2.55

Cytotoxic T cells and viral hepatitis. J Clin Invest (1997) 2.46

Prospects for a vaccine against the hepatitis C virus. Nature (2005) 2.38

Genetic history of hepatitis C virus in East Asia. J Virol (2008) 2.20

Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. Virology (1996) 2.18

Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J Immunol (1999) 1.73

Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry. J Virol (2002) 1.66

Normal lymphocyte development but delayed humoral immune response in CD81-null mice. J Exp Med (1997) 1.59

Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines (2011) 1.37

Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology (2002) 1.33

Hepatitis C virus infection activates the immunologic (type II) isoform of nitric oxide synthase and thereby enhances DNA damage and mutations of cellular genes. J Virol (2004) 1.30

The hepatitis C virus persistence: how to evade the immune system? J Biosci (2003) 1.29

Polynucleotide modulation of the protease, nucleoside triphosphatase, and helicase activities of a hepatitis C virus NS3-NS4A complex isolated from transfected COS cells. J Virol (1997) 1.25

Molecular virology of hepatitis C virus (HCV): 2006 update. Int J Med Sci (2006) 1.24

Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines (2009) 1.16

Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol (2003) 1.13

Genetic immunization: a new era in vaccines and immune therapeutics. FASEB J (1997) 1.05

Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine (2008) 1.04

Anti-hepatitis C virus activity of tamoxifen reveals the functional association of estrogen receptor with viral RNA polymerase NS5B. J Biol Chem (2007) 0.99

Hepatitis C virus (HCV) E1 and E2 protein regions that specifically bind to HepG2 cells. J Hepatol (2002) 0.95

Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection. J Gen Virol (2005) 0.95

Nonstructural protein 3 of hepatitis C virus blocks the distribution of the free catalytic subunit of cyclic AMP-dependent protein kinase. J Virol (1997) 0.95

The immunopathogenesis of hepatitis C virus infection. Clin Liver Dis (2001) 0.95

The challenge of developing a vaccine against hepatitis C virus. J Hepatol (2002) 0.94

Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen. Genet Vaccines Ther (2009) 0.93

Artificial neural network analysis in preclinical breast cancer. Cell J (2013) 0.89

Treatment and vaccination for hepatitis C: present and future. J Ayub Med Coll Abbottabad (2008) 0.88

Retracted Molecular biology of hepatitis C infection. Liver Transpl (2000) 0.88

Progress towards a hepatitis C virus vaccine. Emerg Microbes Infect (2013) 0.87

DNA vaccines. Curr Mol Med (2001) 0.87

A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice. Antiviral Res (2009) 0.86

Recent advances in DNA vaccine of hepatitis virus. Hepatobiliary Pancreat Dis Int (2002) 0.80

Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia. Antivir Ther (2003) 0.79

Challenges for development of hepatitis C virus vaccines. FEMS Microbiol Rev (1994) 0.79

Enhancement of DNA Vaccine-induced Immune Responses by Influenza Virus NP Gene. Immune Netw (2009) 0.78

Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity. Virol Sin (2013) 0.78

Immunogenicity of a purified fragment of 17D yellow fever envelope protein. J Infect Dis (1990) 0.77

Hepatitis C vaccine hampered by viral complexity, many technical restraints. J Natl Cancer Inst (1999) 0.76

Virotherapy in cancer. Iran J Cancer Prev (2013) 0.76

Cellular immune response to infection by different genotypes of hepatitis C virus. Indian J Clin Biochem (2009) 0.76

Articles by these authors

Artificial neural network analysis in preclinical breast cancer. Cell J (2013) 0.89

Evaluation of iNOS Expression in Esophageal Cancer Patients. Gastrointest Tumors (2016) 0.75